The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Yureneva S.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Current guidelines for the treatment of polycystic ovary syndrome: benefits of oral contraceptives with antiandrogenic progestins

Authors:

Yureneva S.V., Il'ina L.M.

More about the authors

Journal: Russian Journal of Human Reproduction. 2017;23(4): 56‑64

DOI: 10.17116/repro201723456-64

Read: 92944 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT GUIDELINES FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME: BENEFITS OF ORAL CONTRACEPTIVES WITH ANTIANDROGENIC PROGESTINS
CURRENT GUIDELINES FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME: BENEFITS OF ORAL CONTRACEPTIVES WITH ANTIANDROGENIC PROGESTINS

To cite this article:

Yureneva SV, Il'ina LM. Current guidelines for the treatment of polycystic ovary syndrome: benefits of oral contraceptives with antiandrogenic progestins. Russian Journal of Human Reproduction. 2017;23(4):56‑64. (In Russ.)
https://doi.org/10.17116/repro201723456-64

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Features of the course of indu­ced pregnancy during the transfer of a thawed embryo in women with poly­cystic ovary syndrome. Russian Journal of Human Reproduction. 2025;(1):54-62
Reproductive function in patients with signs of poly­cystic ovary syndrome. Russian Journal of Human Reproduction. 2025;(6):60-69
Sleep characterization — a marker of meta­bolic health: acti­graphy data. Russian Journal of Preventive Medi­cine. 2025;(5):69-74
Triglycerides-Glucose Index as an inte­gral biomarker of insu­lin resi­stance and cardiovascular diseases. Russian Journal of Preventive Medi­cine. 2025;(5):124-129
Myokines — the cardiometabolic risk pote­ntial biomarkers. Russian Journal of Preventive Medi­cine. 2025;(7):119-126
«Metabolic health» and endo­thelial function in women with poly­cystic ovary syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):27-34
Predictors of cardiovascular outcomes in indi­viduals with different obesity phenotypes. Russian Journal of Preventive Medi­cine. 2025;(11):59-65
Abstract:

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. The evidence-based guidelines recommend hormonal contraceptives, including combined oral contraceptives, as the first-line therapy for menstrual abnormalities and hirsutism/acne. Because of favorable pharmacological properties of progestin, drospirenone-containing forms may have benefits for decreasing cardiometabolic risks factors, associated with PCOS. Combined oral contraceptives with folates may possibly program cardiometabolic health of the offspring in these patients.

Keywords:

polycystic ovary syndrome
hyperandrogenism
cardiometabolic risk
drospirenone-containing oral contraceptives
polycystic ovary syndrome
hyperandrogenism
cardiometabolic risk
drospirenone-containing oral contraceptives
polycystic ovary syndrome
hyperandrogenism
cardiometabolic risk
drospirenone-containing oral contraceptives

Authors:

Yureneva S.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Close metadata

References:

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic Ovary Syndrome (PCOS). Hum Reprod. 2004;19:41-47. https://doi.org/10.1093/humrep/deh098
  2. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and metaanalysis. Hum Reprod. 2016;31(12):2841-2855. https://doi.org/10.1093/humrep/dew218
  3. Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M, Schwartz SM, Lewis CE, Williams OD, Siscovick DS, Bibbins-Domingo K. Polycystic ovary syndrome and risk for longterm diabetes and dyslipidemia. Obstet Gynecol. 2011;117(1):6-13. https://doi.org/10.1097/AOG.0b013e31820209bb
  4. Joham AE, Raniasinha S, Zoungas S, Moran L, Teede HJ. Gestational diabetes and type 2 diabetes in reproductive aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99(3):e447-e452. https://doi.org/10.1210/jc.2013-2007
  5. Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015;136(1):99-103.
  6. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. https://doi.org/10.1016/j.ygyno.2014.11.012
  7. Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, Blackledge H, Khunti K, Howlett TA. Diabetes and cardiovascular events in women with polycystic ovary syndrome. A 20-year retrospective cohort study. Clin Endocrinol.2013;78(6):926-934. https://doi.org/10.1111/cen.12068
  8. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565-4592. https://doi.org/10.1210/jc.2013-2350
  9. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H F, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R,Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO on behalf of the ESE PCOS Special Interest Group, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171:1-29. https://doi.org/10.1530/EJE-14-0253
  10. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. December 3-5, 2012. https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf
  11. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2006;86 Suppl 1:S13-S14. https://doi.org/10.1210/edrv.18.6.0318
  12. Hannemann MM, Alexander HM, Cope NJ, Acheson N. Endometrial hyperplasia: a clinician’s review. Obstet Gynaecol Reprod Med. 2010;20(4):116-120. https://doi.org/10.1016/j.ogrm.2010.01.002
  13. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59(5):368-378. https://doi.org/10.1097/00006254-200405000-00025
  14. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006;12(21):6373-6810. https://doi.org/10.1158/1078-0432.CCR-06-0912
  15. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. The Lancet Oncology. 2015;16(9):1061-1070. https://doi.org/10.1016/S1470-2045(15)00212-0
  16. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003—2008. Am J Obstet Gynecol. 2012;207:377.e1-e377.e8. https://doi.org/10.1016/j.ajog.2012.08.007
  17. Bitzer J, Amy J-J, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, Darney PD, Vicente LF, Gemzell-Danielsson K, Imthurn B, Jensen JT, Kaunitz AM, Kubba A, Lech MM, Mansour D, Merki G, Rabe T, Sedlecki K, Serfaty D, Seydoux J, Shulman LP, Sitruk-Ware R, Skouby SO, Szarewski A, Trussell J, Westhoff C. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care. 2013 Jul;39(3):156-159. https://doi.org/10.1136/jfprhc-2013-100624
  18. Dinger JC, Heinemann LAJ, Kuehl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344-354. https://doi.org/10.1016/j.contraception.2006.12.019
  19. Eichinger S, Evers JLH, Glasier A, La Vecchia C, Martinelli I, Skouby S, Somigliana E, Baird DT, Benagiano G, Crosignani PG, Gianaroli L, Negri E, Volpe A, ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update. 2013;19(5):471-482. https://doi.org/10.1093/humupd/dmt028
  20. World Health Organization. Medical eligibility criteria for contraceptive use, 4th ed. 2009. Available at:whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. Accessed July 13, 2012.
  21. US Centers for Disease Control and Prevention: US medical eligibility criteria for contraceptive use, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(RR-4):1-86.
  22. Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Update. 2006;12:169-178.
  23. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Human Reproduction. 2007;22:317-322. https://doi.org/10.1093/humrep/del407
  24. Gourdy P. Diabetes and oral contraception. Best Pract Res Clin Endocrinol Metab. 2013;27:67-76. https://doi.org/10.1016/j.beem.2012.11.001
  25. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13-24. https://doi.org/10.1016/j.beem.2012.09.004
  26. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8(Suppl 3):4-12. https://doi.org/10.1080/13697130500330382
  27. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012;18:146-170. https://doi.org/10.1093/humupd/dmr042
  28. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817-2823. https://doi.org/10.1210/jc.2003-031158
  29. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women wth polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007;12:30-35. https://doi.org/10.1080/13625180600983082
  30. De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007 88:113-117. https://doi.org/10.1016/j.fertnstert.2006.11.137
  31. Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol. 2007;23:38-44. https://doi.org/10.1080/09637480601137066
  32. Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98(4):1053-1059. https://doi.org/10.1016/j.fertnstert.2012.06.035
  33. Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163-165. https://doi.org/10.1783/1471189041261636
  34. Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J. Efficacy and safety of 3 mg drospirenone /20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception. 2008;77:249-245. https://doi.org/10.1016/j.contraception.2007.11.003
  35. Lortscher D, Admani S, Stur N, Eichenfield LF. Hormonal contraceptives and acne: a retrospective analysis of 2147 patients. J Drugs Dermatol. 2016;15(6):670-674.
  36. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;6:CD004425. https://doi.org/10.1002/14651858.CD004425.pub6
  37. Global Alliance to Improve Outcomes in Acne Group Thiboutot D, Gollnick H. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60:1-50. https://doi.org/10.1016/j.jaad.2009.01.019
  38. Javanbakht AM, Pour HM, Tarrahic MJ. Effects of oral isotretinoin on serum folic acid levels. J Drugs Dermatol. 2012 Sep;11(9):e23-e24.
  39. Fauser BC, Tarlatzis BC, Rebar R, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28-38. https://doi.org/10.1016/j.fertnstert.2011.09.024
  40. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005552. https://doi.org/10.1002/14651858.CD005552.pub2
  41. Gaspard U, Scheen A, Endrikat J, Buicu C, Lefebvre P, Gerlinger C, Heithecker R. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003;67:423-429. https://doi.org/10.1016/S0010-7824(02)00537-1
  42. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger R, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004;69:271-278. https://doi.org/10.1016/j.contraception.2003.11.003
  43. Palacios S, Foidart JM, Genazzani A. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006;55:297-307. https://doi.org/10.1016/j.maturitas.2006.07.009
  44. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of the new oral contraceptive containing an anti-mineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816-1821. https://doi.org/10.1210/jcem.80.6.7775629
  45. Caprio M, Antelmi A, Chetrite, Muscat A, Mammi C, Marzolla V, Fabbri A, Zennaro MC, Fève B. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152(1):113-125. https://doi.org/10.1210/en.2010-0674
  46. Atabekoglu CS, Sükür YE, Kahraman K, Özmen B, Sönmezer M, Berker B. Comparison of two oral contraceptive forms Containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome. IFFS/ASRM 2013 Annual Meeting Abstracts. Fertil Steril. 2013;100(3Suppl):S348. https://doi.org/10.1016/j.fertnstert.2013.07.810
  47. Mancini F, Cianciosi A, Persico N, Facchinetti F, Busacchi P, Battaglia C. Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol. 2010;202(2):169.e1-e8. https://doi.org/10.1016/j.ajog.2009.09.038
  48. Maleedhu P, Vijayabhaskar M, Sharma SSB, Kodumuri PK, Devi DV. Status of homocysteine in Polycystic Ovary Syndrome (PCOS). J Clin Diagn Res. 2014;8(2):31-33. https://doi.org/10.7860/JCDR/2014/7070.3999
  49. Meng Y, Chen X, Peng Z, Liu X, Sun Y, Dai S. Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and metaanalysis. PLoS ONE. 2016;11(6):e0157389. https://doi.org/10.1371/journal.pone.0157389
  50. Kilicdag EB, Bagis T, Tarim E, Aslan E, Erkanli S, Simsek E, Haydardedeoglu B, Kuscu E. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod. 2005;20(6):1521-1528. https://doi.org/10.1093/humrep/deh825
  51. Doherty DA, Newnham JP, Bower C, Hart R. Implications of polycystic ovary syndrome for pregnancy and for the health of offspring. Obstet Gynecol. 2015;125:1399-1408. https://doi.org/10.1097/AOG.0000000000000852
  52. Dunlap B, Shelke K, Salem SA, Keith LG. Folic acid and human reproduction—ten important issues for clinicians. J Exp Clin Assist Reprod. 2011;8:2.
  53. Khoshnood B, Greenlees R, Loane M, Dolk H. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Res A Clin Mol Teratol. 2011;91(suppl 1):S16-S22. https://doi.org/10.1002/bdra.20776
  54. Wang G, Hu FB, Mistry KB, Zhang C, Ren F, Huo Y, Paige D, Bartell T, Hong X, Caruso D, Ji Z, Chen Z, Ji Y, Pearson C, Ji H, Zuckerman B, Cheng TL, Wang X. Association between maternal prepregnancy body mass index and plasma folate concentrations with child metabolic health. JAMA Pediatr. 2016;170(8):e160845. https://doi.org/10.1001/jamapediatrics.2016.0845
  55. Krikke GG, Grooten IJ, VrijKotte TGM, van Eijsden M, Roseboom TJ, Painter RC. Vitamin B12 and folate status in early pregnancy and cardiometabolic risk factors in the offspring at age 5—6 years: findings from the ABCD multi-ethnic birth cohort. BJOG. 2016;123(3):384-392. https://doi.org/10.1111/1471-0528.13574
  56. Wang H, Mueller NT, Li J, Sun N, Huo Y, Ren F, Wang X. Association of maternal plasma folate and cardiometabolic risk factors in pregnancy with elevated blood pressure of offspring in childhood. Am J Hypertens. 2017;30(5):532-540. https://doi.org/10.1093/ajh/hpx003
  57. Orsi CM, Hale DE, Lynch JL. Pediatric obesity epidemiology. Curr Opin Endocrinol Diabetes Obes. 2011;18:14-22. https://doi.org/10.1097/MED.0b013e3283423de1
  58. Gaskins AJ, Rich-Edwards JW, Hauser R. More maternal prepregnancy folate intake and risk of spontaneous abortion and stillbirth. Obstet Gynecol. 2014;124(1):23-31. https://doi.org/10.1097/AOG.0000000000000343
  59. Martinussen MP, Bracken MB, Triche EW, Jacobsen GW, Risnes KR. Folic acid supplementation in early pregnancy and the risk of preeclampsia, small for gestational age offspring and preterm delivery. Eur J Obstet Gynecol Reprod Biol. 2015;195:94-99. https://doi.org/10.1016/j.ejogrb.2015.09.022
  60. Hodgetts VA, Morris RK, Francis A, Gardosi J, Ismail KM. Effectiveness of folic acid supplementation in pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review and metaanalysis. BJOG. 2015 Mar;122(4): 478-490. https://doi.org/10.1111/1471-0528.13202
  61. Folic acid supplementation for the prevention of neural tube defects. US preventive services task force recommendation statement. JAMA. 2017;317(2):183-189. https://doi.org/10.1001/jama.2016.19438 Поступила 04.08.17
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.